卵圆孔未闭与卒中:综述
本综述指出PFO见于约25%成人,反常栓塞约占全部卒中的5%、年轻患者的10%。≤60岁隐源性卒中患者中约50%存在PFO,而一般人群为25%。RoPE评分和PASCAL分类(结合RoPE评分与超声心动图解剖标准)用于判断PFO是否为卒中病因。6项试验汇总分析(3740例)显示,PFO封堵组卒中年发生率0.47% vs 药物治疗组1.09%(校正HR 0.41)。PASCAL「可能」组2年复发缺血性卒中相对率降低90%(HR 0.10),绝对风险降低2.1%;「不太可能」组封堵未降低复发率且不良事件风险更高。
要点
- ≤60岁隐源性卒中患者约50%存在PFO,一般人群约25%,提示PFO与青年隐源性卒中相关。
- RoPE评分<3分者PFO患病率23%(与一般人群相似),9–10分者达77%。
- 6项试验汇总(3740例)显示,PFO封堵组卒中年发生率0.47% vs 药物治疗组1.09%,校正HR 0.41(95%CI 0.28–0.60)。
- PASCAL「可能」组(年轻、无血管危险因素、高危PFO解剖特征)封堵后2年复发缺血性卒中HR 0.10(95%CI 0.03–0.35),绝对风险降低2.1%(95%CI 0.9%–3.4%)。
- PASCAL「不太可能」组(如老年、有血管危险因素、无高危PFO解剖特征)封堵未降低复发率,且房颤等操作/器械相关不良事件风险更高。
适用人群与场景
- ≤60岁隐源性卒中(不明来源栓塞性卒中)患者,PFO患病率约50%;一般成人PFO患病率约25%。
- PASCAL「可能」组:较年轻、无血管危险因素、伴高危PFO解剖特征者;PASCAL「不太可能」组:如较年长、有血管危险因素、无高危PFO解剖特征者。
诊断标准与关键阈值
- RoPE评分纳入年龄、卒中或短暂性脑缺血发作史、糖尿病、高血压、吸烟、影像学皮质梗死等临床特征,预测隐源性卒中由PFO所致的可能性;评分<3分者PFO患病率23%,9–10分者77%。
- PASCAL分类系统结合RoPE评分与超声心动图解剖标准(大分流、房间隔瘤),将PFO归类为隐源性卒中的「可能」「可能有关」或「不太可能」病因。
处置流程与药物剂量
- 经皮PFO封堵可降低≤60岁隐源性卒中患者的复发性缺血性卒中风险;PASCAL「可能」组2年复发缺血性卒中HR 0.10(95%CI 0.03–0.35),绝对风险降低2.1%(95%CI 0.9%–3.4%)。
- PASCAL「不太可能」组行PFO封堵未降低复发卒中率,且操作和器械相关不良事件(如房颤)风险更高。
研究设计与关键结果
- 综述汇总:PFO见于约25%成人;反常栓塞约占全部卒中5%、年轻患者卒中10%;≤60岁隐源性卒中患者约50%有PFO。
- 6项试验汇总分析(3740例)中位随访57个月,PFO封堵组卒中年发生率0.47%(95%CI 0.35%–0.65%)vs 药物治疗组1.09%(95%CI 0.88%–1.36%),校正HR 0.41(95%CI 0.28–0.60)。
- 各试验人群间封堵的获益与危害高度异质。
- PASCAL「可能」组封堵后2年复发缺血性卒中相对率降低90%(HR 0.10,95%CI 0.03–0.35),绝对风险降低2.1%(95%CI 0.9%–3.4%)。
- PASCAL「不太可能」组封堵未降低复发卒中率,且操作和器械相关不良事件(如房颤)风险更高。
证据类型、等级与局限
- 证据类型:综述;汇总分析纳入6项试验、3740例患者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对≤60岁隐源性卒中患者,可用RoPE评分与PASCAL分类(结合超声心动图大分流、房间隔瘤)评估PFO为病因的可能性,以筛选PFO封堵的获益人群。
- PASCAL「可能」组(年轻、无血管危险因素、高危PFO解剖特征)行经皮PFO封堵可大幅降低卒中复发;「不太可能」组封堵未降低复发率且不良事件风险更高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A patent foramen ovale (PFO), an opening between the right and left atria during normal fetal development that fails to close after birth, is present in approximately 25% of all adults. Paradoxical embolism, a venous thromboembolism that travels to the systemic circulation typically through a PFO, accounts for about 5% of all strokes and 10% of strokes in younger patients.
OBSERVATIONS: Approximately 50% of patients 60 years or younger with an embolic stroke of undetermined source (cryptogenic stroke) have a PFO, compared with 25% of the general population. The Risk of Paradoxical Embolism (RoPE) score incorporates clinical characteristics (age, history of stroke or transient ischemic attack, diabetes, hypertension, smoking, cortical infarct on imaging) to predict the likelihood that embolic stroke of undetermined source was caused by a PFO. Among patients in the lowest RoPE score category (score <3), PFO prevalence was similar to that in the general population (23%), while PFO prevalence was 77% in patients with a RoPE score of 9 or 10. The PFO-Associated Stroke Causal Likelihood (PASCAL) classification system combines the RoPE score and anatomical criteria from echocardiography (large shunt, atrial septal aneurysm) to classify PFO as the "probable," "possible," or "unlikely" cause of otherwise cryptogenic stroke. PFO closure reduces recurrent ischemic stroke in patients 60 years or younger with cryptogenic stroke. In a pooled analysis of 6 trials (3740 patients), the annualized incidence of stroke over a median follow-up of 57 months was 0.47% (95% CI, 0.35%-0.65%) with PFO closure vs 1.09% (95% CI, 0.88%-1.36%) with medical therapy (adjusted hazard ratio, 0.41 [95% CI, 0.28-0.60]). However, the benefits and harms of closure were highly heterogeneous across the trial populations. In patients categorized as PASCAL "probable" (ie, younger patients without vascular risk factors and high-risk PFO anatomical features), there was a 90% decreased relative rate of recurrent ischemic stroke after PFO closure at 2 years (hazard ratio, 0.10 [95% CI, 0.03-0.35]; absolute risk reduction, 2.1% [95% CI, 0.9%-3.4%]). PASCAL "unlikely" patients (eg, older patients with vascular risk factors and no high-risk PFO anatomical features) did not have a lower recurrent stroke rate with PFO closure but had higher risk of procedure- and device-related adverse events, such as atrial fibrillation.
CONCLUSIONS AND RELEVANCE: Patent foramen ovale is present in approximately 25% of all adults and is a common cause of stroke in young and middle-aged patients. The PASCAL classification system can help guide patient selection for PFO closure. Percutaneous PFO closure substantially reduces the risk of stroke recurrence in well-selected patients younger than 60 years after cryptogenic stroke.
参考来源
- Kent DM, Wang AY. Patent Foramen Ovale and Stroke: A Review. JAMA. 2025. PMID: 40720119. doi:10.1001/jama.2025.10946
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。